NCT05845827

Brief Summary

Cardiorespiratory fitness (CRF), also known as "exercise capacity", is the capacity of respiratory and circulatory systems to supply oxygen to skeletal muscle during exercise for the generation of energy. Determinants of CRF include lung capacity, capillary density, cardiac output, hemoglobin concentration, and mitochondrial function. The research group studies how CRF is related to fuel utilization, yielding a mechanistic understanding of the association between lower CRF and worsening metabolic health via mitochondrial function. The objective of this study is to measure fuel utilization in response to habitual diet for one week in adolescents and young adults, ages 14-22 years (n=30). Fuel utilization will be estimated by glucose measures using a continuous glucose monitor (CGM). Habitual dietary intake will be collected via a mobile phone application (BiteAI, Inc) that uses artificial intelligence to extract nutrient information from food photographs. Participants will undergo two standard of care (SOC) meal tolerance tests at home - a glucose tolerance test and a Ensure® mixed meal tolerance test. CRF will be estimated by measuring maximum oxygen consumption (VO2 max) during a graded treadmill test. The hypothesis is that a higher VO2 max will be associated with increased fuel utilization, measured by lower glucose response to the SOC meal tolerance tests. The proposed study is described in the following aims: SPECIFIC AIM 1. Test for feasibility of completion of self-report dietary food records, completion of two at home meal tolerance tests that are standard of care for metabolic health screening, and completion of a seven-day continuous glucose monitor. SPECIFIC AIM 2. Identify nutrients and foods that are associated with an elevated glucose response. SPECIFIC AIM 3. Assess the influence of VO2 max on the glucose response to the SOC glucose tolerance test and Ensure® mixed meal tolerance test.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jun 2023

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 14, 2023

Completed
22 days until next milestone

First Posted

Study publicly available on registry

May 6, 2023

Completed
2 months until next milestone

Study Start

First participant enrolled

June 20, 2023

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2023

Completed
Last Updated

February 29, 2024

Status Verified

February 1, 2024

Enrollment Period

6 months

First QC Date

April 14, 2023

Last Update Submit

February 28, 2024

Conditions

Outcome Measures

Primary Outcomes (3)

  • Number of dietary records completed by each study participant

    The researchers will measure dietary intake using a mobile phone application called BiteSnap. The goal is to have participants report \>90% of their meals using mobile phone photos to extract nutrient information.

    7-10 days

  • Number of days wearing the continuous glucose monitor

    The researchers will measure the amount of time each participant wears the continuous glucose monitor. The goal is to have participants wear the monitor for \>90% of the time in the study.

    7-10 days

  • Completion of the at-home glucose tolerance test

    Participants will be asked to drink a 75-gram glucose tolerance test. The researchers will measure the number of participants that self-reported drinking the shake at fasting. The goal will be 90% of participants self-report drinking the shake at fasting.

    7-10 days

Secondary Outcomes (2)

  • Identify nutrients associated with an elevated glucose response, measured by the continuous glucose monitor.

    7-10 days

  • Access the relationship between fitness levels and glucose response to standard of care meal tests.

    7-10 days

Eligibility Criteria

Age14 Years - 22 Years
Sexall
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Adolescents and young adults, ages 14-22 years

You may qualify if:

  • Adolescents and young adults, ages 14-22 years

You may not qualify if:

  • Previous diagnosis of type 1 or 2 diabetes
  • Previous diagnosis of hyperlipidemia or other metabolic disease
  • Use of medications known to affect glucose metabolism (metformin, oral steroids, sulfonylureas, insulin).
  • Allergies to milk.
  • Inability to participant in the maximal exercise test on the treadmill.
  • Individuals not having android or IOS phones
  • Individuals who cannot speak and/or write in English.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Dartmouth-Hitchcock Medical Center

Lebanon, New Hampshire, 03756, United States

Location

Related Publications (1)

  • Ge M, Lebby SR, Chowkwale S, Harrison C, Palmer GM, Loud KJ, Gilbert-Diamond D, Vajravelu ME, Meijer JL. Impact of Dietary Intake and Cardiorespiratory Fitness on Glycemic Variability in Adolescents: An Observational Study. Curr Dev Nutr. 2025 Jan 21;9(2):104547. doi: 10.1016/j.cdnut.2025.104547. eCollection 2025 Feb.

Biospecimen

Retention: SAMPLES WITH DNA

Plasma and buffy coat will be extracted from one blood sample (10mL).

MeSH Terms

Conditions

Glucose Metabolism DisordersFeeding BehaviorPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Condition Hierarchy (Ancestors)

Metabolic DiseasesNutritional and Metabolic DiseasesBehavior, AnimalBehaviorLeukemia, LymphoidLeukemiaNeoplasms by Histologic TypeNeoplasmsHematologic DiseasesHemic and Lymphatic DiseasesLymphoproliferative DisordersLymphatic DiseasesImmunoproliferative DisordersImmune System Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor of Medicine

Study Record Dates

First Submitted

April 14, 2023

First Posted

May 6, 2023

Study Start

June 20, 2023

Primary Completion

December 31, 2023

Study Completion

December 31, 2023

Last Updated

February 29, 2024

Record last verified: 2024-02

Data Sharing

IPD Sharing
Will not share

Locations